证券代码：300451 证券简称：创业慧康 公告编号：2026-004 创业慧康科技股份有限公司 关于筹划控制权变更事项进展暨协议转让股份完成过户 登记的公告 行事项（"向特定对象发行股票"）。此外，杭州更好拟向公司提名四名非独立 董事、两名独立董事人选（"董事会改选"）。无论公司是否完成向特定对象发 行股票事项，若杭州更好提名的上述董事全部当选且占公司董事会席位的半数以 上，将导致公司控制权变更，杭州更好成为公司的控股股东。 3、根据中国证券登记结算有限责任公司出具的《证券过户登记确认书》，本 次协议转让所涉及的股份已于 2026 年 2 月 11 日办理完成了过户登记手续。杭州 更好拥有公司股份 96,525,096 股，占公司总股本的 6.23%。 4、公司股东筹划控制权变更事项仍在进行中，董事会改选、向特定对象发行 股票等事项能否最终实施完成及实施结果尚存在不确定性。公司将持续关注后续 进展情况，并督促相关股东及时履行信息披露义务，敬请广大投资者理性投资， 注意投资风险。 一、协议转让概述 2025 年 11 月 12 日，杭州更好与葛航先生签署《股份转让协议》，受让葛 航先生持有的公司 96,525 ...

Core Viewpoint - The financial performance of Chuangyue Huikang (300451) shows significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and market position [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 862 million yuan, a year-on-year decrease of 26.26% [2]. - The net profit attributable to shareholders was -122 million yuan, reflecting a year-on-year decline of 331.69% [2]. - The net profit excluding non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the single-quarter main revenue was 285 million yuan, a decrease of 35.5% compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, down 264.2% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -47.40 million yuan, a decline of 288.66% year-on-year [2]. - The company's debt ratio stood at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan [2]. - The gross profit margin was reported at 49.87% [2]. Business Operations - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations [2]. - The company's offerings now include smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative solutions for system construction and operation services [2].

Core Viewpoint - The company emphasizes that the clawdbot has no direct impact on its existing business and is committed to advancing its "Huikang Cloud Strategic Planning" to enhance product innovation and system reliability [1] Group 1: Business Strategy - The company will focus on continuous product innovation and the deepening of core system applications, particularly HI-HIS, to improve system reliability and data security [1] - The company aims to optimize implementation processes and build a standardized delivery system to ensure efficient project execution [1] - Collaboration with ecosystem partners will be prioritized to integrate medical scene demands with cutting-edge technology, accelerating the transformation of R&D results [1] Group 2: Competitive Advantage - The company plans to strengthen its product technology barriers and core competitive advantages through enhanced development support and operational knowledge accumulation [1] - A standardized toolchain will be established to improve the professional capabilities of the delivery team, alongside a rapid deployment mechanism to address short-term market challenges [1] Group 3: Market Outlook - The company expresses confidence in the broad prospects of the medical information industry and the ongoing core demands of clients [1] - With enhanced product technology strength, improved project delivery efficiency, and innovative applications in the medical AI field, the company will continue to deepen its focus on the medical information sector [1] - The company aims to explore new models and paths for smart hospital construction in collaboration with various medical institutions, contributing to high-quality development in healthcare [1]

Group 1 - The stock price of Chuangye Huikang (300451) closed at 5.51 yuan on February 9, 2026, with an increase of 3.18% and a trading volume of 501,700 hands, resulting in a transaction amount of 275 million yuan [1] - On February 9, 2026, the net outflow of main funds was 1.826 million yuan, accounting for 0.66% of the total transaction amount, while retail investors had a net inflow of 5.7344 million yuan, accounting for 2.09% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net inflows from retail investors on several days despite overall negative net flows from main and speculative funds [1] Group 2 - Chuangye Huikang's total market value is 8.536 billion yuan, which is below the software development industry average of 13.721 billion yuan, ranking 77 out of 193 [2] - The company reported a net profit of -122 million yuan for the first three quarters of 2025, a significant decline of 331.69% year-on-year, with a gross margin of 49.87% [2] - The company's main business has shifted from product development and sales to a broader range of services, including smart healthcare, internet medical services, and health city solutions [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chuangyue Huikang (300451) as of February 5, 2026, showing a decline in stock price and significant net outflows from various investor categories [1][2]. Group 2 - Chuangyue Huikang reported a main revenue of 862 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 26.26% [2]. - The company experienced a net profit attributable to shareholders of -122 million yuan, a significant decline of 331.69% year-on-year [2]. - The net profit after deducting non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the company’s single-quarter main revenue was 285 million yuan, reflecting a 35.5% year-on-year decrease [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, a decline of 264.2% year-on-year [2]. - The company’s debt ratio stands at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan, while the gross profit margin is 49.87% [2]. Group 3 - Chuangyue Huikang's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations, including areas such as smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative operational services [2].

Group 1 - Company Chuangyue Huikang Technology Co., Ltd. won a procurement project from China Construction Bank Liaoning Branch with a bid amount of 1.8 million yuan [1] - In 2024, the company's operating revenue was 1.423 billion yuan, with a revenue growth rate of -11.96% [2][3] - The net profit attributable to the parent company for 2024 was -174 million yuan, with a net profit growth rate of -572.96% [2][3] Group 2 - In the first half of 2025, the company's operating revenue was 577 million yuan, with a revenue growth rate of -20.65% [2][3] - The net profit attributable to the parent company for the first half of 2025 was -81 million yuan, with a net profit growth rate of -394.25% [2][3] - The company operates in the information technology industry, with main product types including industry-specific software, service (39.86%), software sales (39.55%), system integration and operation maintenance (10.74%), and hardware sales and others (9.85%) [2][3]

Core Viewpoint - The company Chuangying Huikang (300451) has experienced significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 862 million yuan, a year-on-year decrease of 26.26% [2]. - The net profit attributable to shareholders was -122 million yuan, reflecting a year-on-year decline of 331.69% [2]. - The net profit excluding non-recurring items was -142 million yuan, down 382.12% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 285 million yuan, a decrease of 35.5% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -41.67 million yuan, a decline of 264.2% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -47.40 million yuan, down 288.66% year-on-year [2]. - The company's debt ratio stood at 20.27%, with investment income of 4.44 million yuan and financial expenses of -5.32 million yuan [2]. - The gross profit margin was reported at 49.87% [2]. Business Operations - The company's main business has shifted from primarily product development and sales to a broader focus on system construction, services, and operations [2]. - Key areas of expansion include smart healthcare, internet medical services, medical IoT, health big data, smart health cities, and innovative solutions for smart medical insurance [2].

Core Viewpoint - The company, Chuangye Huikang (300451), is currently in the process of planning a change in control, and there are no undisclosed matters as of now. The company will comply with relevant regulations for information disclosure if there are any updates [1]. Group 1 - The company is in the process of planning a change in control [1] - As of now, there are no undisclosed matters that need to be reported [1] - The company commits to strict compliance with information disclosure regulations for any future developments [1]

Core Viewpoint - The company expects a net loss attributable to shareholders of 305 million to 405 million yuan for the fiscal year 2025, compared to a loss of 174 million yuan in the same period last year [1] Group 1: Financial Performance - The company's loss situation has worsened during the reporting period, with a significant increase in expected losses [1] - The anticipated net loss for 2025 is projected to be between 305 million and 405 million yuan, indicating a decline in financial performance compared to the previous year's loss of 174 million yuan [1] Group 2: Operational Challenges - The company faces dual pressures on its operations due to the industry and policy environment, which has led to a temporary contraction in client investment in information technology [1] - The new generation HI-HIS product is currently in a critical phase of market introduction and adjustment, limiting its short-term contribution to performance, although long-term potential remains promising [1] - Changes in the competitive landscape have compressed the industry's profit margins, further impacting the company's financial health [1] Group 3: Strategic Investments - The company continues to invest heavily in its AI strategy, resulting in high research and development expenses that are negatively affecting short-term profit performance [1] - Some subsidiaries have not met expected profitability levels, leading to an anticipated goodwill impairment provision of approximately 100 million to 130 million yuan [1]

证券代码：300451 证券简称：创业慧康 公告编号：2026-003 创业慧康科技股份有限公司 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开 第八届董事会第十四次会议，于 2025 年 5 月 29 日召开 2024 年年度股东大会， 审议通过了《关于续聘会计师事务所的议案》，同意续聘天健会计师事务所（特 殊普通合伙）（以下简称"天健"）担任公司 2025 年度财务审计机构和内部控 制审计机构，具体内容详见公司于 2025 年 4 月 15 日在巨潮资讯网上披露的《关 于续聘会计师事务所的公告》（公告编号：2025-013）。近日，公司收到天健出 具的《关于变更项目质量复核人的函》，现将具体情况公告如下： 一、本次变更的基本情况 天健作为公司 2025 年度财务报表和 2025 年末财务报告内部控制审计机构， 原委派肖瑞峰作为公司2025年度财务报表审计报告和2025年末财务报告内部控 制审计报告的项目质量复核人。由于肖瑞峰工作安排调整，现委派黎永键接替肖 瑞峰作为项目质量复核人。变更后的项目质量复核人为黎永键。 二、本次变更的项目质量复核人员相关信息 项目质量复核人： ...